In line with this causal role, the PI3Kα inhibitor alpelisib in combination with the ER antagonist fulvestrant was clearly superior than fulvestrant alone in patients with advanced ER+/PIK3CA mutant breast cancer13, leading to the approval of alpelisib + fulvestrant in this subgroup of ER+ breast cancers. Here, ESR1 is linked to breast carcinoma.